Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
Rohit
R
Bhargava
David J
DJ
Dabbs
D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000175:diagnosis*; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D019394:Ki-67 Antigen / Q000032:analysis*; D009364:Neoplasm Recurrence, Local / Q000209:etiology*; D011785:Quality Assurance, Health Care; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone